Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 January 1998

Plasminogen activators (tissue type t-PA, urokinase type u-PA) and plasminogen activator inhibitor type 1 (PAI-1) in Graves disease

Danuta Rość, Ewa Zastawna, Wanda Drewniak, Arkadiusz Michalski, Maria Kotschy

Med Sci Monit 1998; 4(6): CR975-978 :: ID: 451753

Abstract

Haemostatic disturbances are observed in thyroid diseases. The fibrinolytic system reaction is suspected to be the cause. There are few data about the nature of fibrinolytic changes in the serum of patients suffering from Graves disease. The aim of our work was to study serum fibrinolytic system changes in Graves disease due to the concentration of plasminogen activators type of tissue (t-PA) and urokinase (u-PA) and plasminogen activator inhibitor type 1 (PAI-1). The study was performed on 33 patients (F/M 29/4, mean aged 35.0 years) with Graves disease and on 34 healthy volunteers(F/M 28/6, mean age: 33.7 years). Graves disease was diagnosed on the basis of clinical and laboratory evidence of thyrotoxicosis, diffuse goitre and absence of other symptoms of thyrotoxicosis. In the citric blood plasma the concentrations of tissue (t-PA) and urokinase (u-PA) plasminogen activators, and plasminogen activator inhibitor type 1 (PAI-1) antigen were determined using ELISA - test (Biopol, Sweden). The individual values of t-PA Ag and PAI-1 Ag in patients with Graves disease were ranged much wider than in control group and the concentration of antigens reached the highest values in several
cases. Mean concentrations of t-PA, u-PA and PAI-1 antigen in blood plasma of patients were significantly increased comparing to the control group. The hyperthyroid goitre in patients suffering from Graves disease seems to be the source of plasminogen activators (t-PA, u-PA) detected in the blood plasma.

Keywords: Graves Disease, fibrinolitic system, Plasminogen Activators, inhibitors

Add Comment 0 Comments

Editorial

01 April 2024 : Editorial  

Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug Resistance

Dinah V. Parums

DOI: 10.12659/MSM.944600

Med Sci Monit 2024; 30:e944600

0:00

In Press

06 Mar 2024 : Clinical Research  

Comparison of Outcomes between Single-Level and Double-Level Corpectomy in Thoracolumbar Reconstruction: A ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943797  

21 Mar 2024 : Meta-Analysis  

Economic Evaluation of COVID-19 Screening Tests and Surveillance Strategies in Low-Income, Middle-Income, a...

Med Sci Monit In Press; DOI: 10.12659/MSM.943863  

10 Apr 2024 : Clinical Research  

Predicting Acute Cardiovascular Complications in COVID-19: Insights from a Specialized Cardiac Referral Dep...

Med Sci Monit In Press; DOI: 10.12659/MSM.942612  

06 Mar 2024 : Clinical Research  

Enhanced Surgical Outcomes of Popliteal Cyst Excision: A Retrospective Study Comparing Arthroscopic Debride...

Med Sci Monit In Press; DOI: 10.12659/MSM.941102  

Most Viewed Current Articles

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750